Biotechnology

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

* Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization * All modules required for regulatory review, including CMC data, are now complete * Submission based on Phase 3 data from ~45K patients demonstrating high efficacy and well-tolerated safety, including a...

2021-10-27 20:30 4153

Abcam completes $340m strategic acquisition and expands kit capacity and capability

- Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan CAMBRIDGE, England, Oct. 27, 2021 /PRNewswire/ -- Abcam

2021-10-27 14:00 4618

I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China

* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...

2021-10-26 20:00 3342

Samsung Biologics Reports Third Quarter 2021 Financial Results

* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...

2021-10-26 15:23 2541

Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818

JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...

2021-10-26 07:30 2293

SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage

SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...

2021-10-25 20:30 2378

Antengene to Host its First R&D Days on November 16 and November 18, 2021

* Virtual Event (in English) on November 16 * On Site Event with Live Webcast (in Mandarin) on Nov 18 SHANGHAI and HONG KONG, Oct. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, deve...

2021-10-25 20:00 4371

Happiness Biotech Acquires Majority Ownership in Fujian Shennong

NANPING, China, Oct. 25, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), aChina-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce solutions, and the sales of automobile, today announced that it...

2021-10-25 20:00 3437

GC Group strengthens Sustainable Growth for business and customers with "Together To Net Zero" Roadmap

* Announcement by leading chemicals company in line with its 'Chemistry for Better Living' commitment, providing clear pathway to improving people's quality of life through transformation to low carbon business * Ambitious plan will use Three-Pillar Low Carbon Transition Framework, focusing o...

2021-10-25 19:05 3023

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer

HOUSTON and SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreem...

2021-10-25 17:00 2052

Meet the Next Resolution in Medicine -- Polaris Biology Releases Starion™, the next-generation mass cytometer

SHANGHAI, Oct. 23, 2021 /PRNewswire/ -- Polaris Biology, a leading innovator in single-cell technologies, announced today the largest product launch in company history with the introduction of the Starion™ Mass Cytometry System. Dr. Yuzhang Wu, and...

2021-10-23 15:05 3593

Technological supremacy reigns in Chengdu

CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- Chengdu, capital of Southwest China's Sichuan province, is accelerating its development driven by technological innovation thanks to the Chengdu Science and Technology Bureau. An employee of Qitan Tech ...

2021-10-22 21:14 4373

2021 Bio-enzyme Application Explorer Summit held in Chengdu

The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...

2021-10-22 14:23 1963

Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences  International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...

2021-10-22 09:00 2380

Aero HygenX Partners with Ethiopian Airlines for Deployment of Autonomous UV-C Disinfecting Solution

* With hygiene in sharp focus, industry support for Aero HygenX continues to grow * Chemical-free disinfection via UV-C light offers a safer work environment for staff and is gentler on aircraft interiors * A global problem requires global solutions: It is the intention of Aero HygenX to ...

2021-10-21 21:57 2907

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

SHANGHAI and HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-10-21 16:00 4372

Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray

SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company")    , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...

2021-10-21 15:58 2046

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...

2021-10-21 10:31 3608

Singapore-based Biosyngen receives 500 million yuan in investment

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- At the 12th Singapore-Guangdong Collaboration Council (SGCC) meeting held online onOctober 20, Singapore-based Biosyngen Pte. Ltd. ("Biosyngen") announced its partnership with wholly state-owned Chinese company Science City (Guangzhou) Investment Group Co....

2021-10-21 09:30 7630

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...

2021-10-21 08:05 2509